Showing results (51-60 of 63) with videos related to
Sort By:
Pageof 7
The New England Journal of Medicine|October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 YearsPaolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)Michael K Wong, Mohammed M Milhem, Joseph J Sacco, et al.The New England Journal of Medicine|September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.Journal for Immunotherapy of Cancer|November 28, 2025
International real-world study of combination immunotherapy sequences in metastatic melanomaMora Guardamagna, Sarah E Lochrin, James William Smithy, et al.The Lancet. Oncology|May 31, 2025
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Michal Kicinski, Caroline Dutriaux, et al.European Journal of Cancer (Oxford, England : 1990)|January 28, 2025
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell CarcinomaJeremy Mo, Anne Zaremba, Andrisha-Jade Inderjeeth, et al.American Journal of Hematology|April 6, 2024
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot studyJosquin Moraly, Julien Rossignol, Claire Rouzaud, et al.European Journal of Cancer (Oxford, England : 1990)|March 16, 2025
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence studyMichael Weichenthal, Eva Ellebaek, Joanna Mangana, et al.Liver International : Official Journal of the International Association for the Study of the Liver|March 30, 2024
Histological characterization of liver involvement in systemic mastocytosisJulien Rossignol, Danielle Canioni, Achille Aouba, et al.The Journal of Allergy and Clinical Immunology|August 26, 2023
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypesLaura Polivka, Marine Madrange, Cristina Bulai-Livideanu, et al.Pageof 7